November 21, 2023 — BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today presented additional Phase 3 data from ATTRibute-CM, its study of acoramidis in transthyretin amyloid cardiomyopathy, or ATTR-CM, at the American Heart Association (AHA

November 21, 2023 — Heuron, a medical AI (artificial intelligence) imaging software solution company, under the leadership of CEO Dr. Donghoon Shin, is scheduled to take part

November 20, 2023 — In the U.S., nearly 10,000 children and adolescents have developed a condition called multisystem inflammatory syndrome, or MIS-C, following 

November 20, 2023 — Abbott announced new late-breaking data that show advanced heart failure patients living with its HeartMate 3 heart pump who didn't receive aspirin as part of th

November 20, 2023 — Student engineers from the University of Bath are on top of the world after winning an international competition to design an artificial heart. 

Team Bath Heart took top prize at the grand final of the first-ever Heart Hackathon, which was held in Texas at the end of October. 

Six members of the team presented their device to global experts in artificial heart technologies, competing against teams from Australia, the United States, Sweden, New Zealand, Romania and Egypt. 

November 20, 2023 — Medtronic plc, a global leader in healthcare technology, announced that the United States Food and Drug Administration (FDA) has approved the Symplicity Spyral renal denervation (RDN) system, also known as the Symplicity blood pressure procedure, for the treatment of hypertension. With this approval, Medtronic will immediately begin commercialization.

November 20, 2023 — A groundbreaking advancement in the treatment of patients with uncontrolled hypertension (HTN) has been achieved with the recent U.S. Food & Drug Administration (FDA) approvals of two renal denervation (RDN) systems. These innovative systems, developed by leading medical technology companies Medtronic, Inc (Symplicity Spyral Renal Denervation System) and ReCor Inc.

Recent recommendations for remote monitoring of implantable devices may require healthcare organizations to rethink how they staff their operations

This past spring, electrophysiology experts issued new recommendations for remote monitoring of cardiovascular implantable electronic devices (CIEDs).

November 17, 2023 — Sudden cardiac arrest remains a deadly and complex condition, but investigators in the Smidt Heart Institute at Cedars-Sinai have discovered a new method—using a widely available cardiovascular test—for predicting the heart malfunction. 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now